Affiliation:
1. University of Medicine and Pharmacy , Research Center of Functional Genomics, Biomedicine, and Translational Medicine Iuliu Hatieganu , Cluj-Napoca , Romania ;
2. Animal Facility University of Medicine and Pharmacy Iuliu-Hatieganu , Cluj-Napoca , Romania ;
Abstract
Abstract
Canine mammary tumors (CMTs) are one of the most common neoplasms in female dogs. Unfortunately, the current diagnosis often occurs in later stages, and there is a pressing need for more comprehensive data on treatment options to improve overall prognosis. Consequently, the early detection of these tumors is critical for improving treatment outcomes and survival rates. As such, biomarkers are essential for improving the diagnosis, treatment, and prognosis of CMT, the reason for which further research is required to enhance our understanding of the disease. The most studied biomarkers for CMT are evaluated from serum and tissue samples using different molecular approaches and relate to proliferation and cell cycle. Several biomarkers were also described regarding cell damage, autophagy and apoptotic-related pathways, hypoxia, angiogenesis, EMT, invasion, metastasis or cancer stem features. Overall, biomarkers have shown the potential to be used as a tool for the early detection of mammary tumors in dogs. However, more research is needed to validate these biomarkers and to develop sensitive and specific diagnostic tests. In this regard, we aimed to review known biomarkers and their role in CMT comprehensively. We also encouraged further investigations of reliable biomarkers that could improve treatment outcomes and survival rates for dogs with this disease.
Reference97 articles.
1. Kaszak I, Ruszczak A, Kanafa S, Kacprzak K, Król M, Jurka P: Current biomarkers of canine mammary tumors. Acta Ve t Scand 2018, 60(1):66.
2. Gherman LM, Chiroi P, Nuţu A, Bica C, Berindan-Neagoe I: Profiling canine mammary tumors: A potential model for studying human breast cancer. Vet J 2023, 303:106055.
3. Gherman ML, Zanoaga O, Budisan L, Raduly L, Berindan-Neagoe I: Doxorubicin as a Potential Treatment Option in Canine Mammary Tumors. Vet Sci 2023, 10(11).
4. Burrai GP, Gabrieli A, Moccia V, Zappulli V, Porcellato I, Brachelente C, Pirino S, Polinas M, Antuofermo E: A Statistical Analysis of Risk Factors and Biological Behavior in Canine Mammary Tumors: A Multicenter Study. Animals (Basel) 2020, 10(9).
5. Tavasoly A, Golshahi H, Rezaie A, Farhadi M: Classification and grading of canine malignant mammary tumors. Vet Res Forum 2013, 4(1):25–30.